News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Venus Remedies now has 29 active product approvals in Vietnam alone
Poviztra is a second brand of Wegovy
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Subscribe To Our Newsletter & Stay Updated
